Abstract: The invention provides a set of novel Single domain VHH antibodies against SARS-CoV-2 (SEQ ID N? 1-6) and their use to detect and neutralize the wild type virus.

Abstract: One-step rapid gradient method for rapid generation of nanoantibodies (HHV) against any antigen. Where the method comprises the separation of nanoantibodies against a specific antigen from a nanoantibody expression library through the following steps: (a) binding the antigen of interest to beads made of protein-binding polymers (b) incubating the microorganisms of the expression library with the pearls of stage (a), (c) placing the beads of step (b) in a tube with an inert medium with a density greater than or equal to 1 g/mL and centrifuge for 45 s to 2 minutes at a rate between 150 and 250 g; d) discarding the upper fraction and supernatant with the free microorganisms, and obtain the beads with the linked microorganisms, which correspond to those that express HHV that recognizes the antigen.

Abstract: This invention relates to an antimicrobial susceptibility test made upon pure microbial cultures—a laboratory culture containing a single species of organism—or directly from biological samples uncultured. Some preferred embodiments do not require the use a pure culture obtained from a biological product which would otherwise take at least 24 hours for the microorganisms to grow—so, is performed an antimicrobial susceptibility test directly from uncultured biological samples like urine, blood cultures or water by fluorescence analysis.

Abstract: The present invention relates to a method for detecting resistant microorganisms to a therapeutic agent in a biological sample, comprising the following steps: a. inoculate the said sample, uncultured, on a first tube with, and on a second tube without, at least one therapeutic agent; preferentially further including at least one lysing agent and/or a buffer, and/or a suitable culture medium, or put the sample on a separation serum tube; and incubated it; b. add to both tubes a fluorescent marker; c. perform a fluorescence analysis for obtaining one or more fluorescence or growth parameters for each of the two tubes; wherein the microorganisms resistant phenotype of the biological sample to said therapeutic agent is obtained by comparing the one or more fluorescence parameters between the two tubes.